When does Jardiance lose exclusivity (and when can a generic launch)?
Jardiance’s generic availability depends on patent and other exclusivity timelines for its active ingredient (empagliflozin). Those dates can differ from “patent expiry” because companies may still be protected by additional patents, regulatory exclusivity, or patent challenges.
For a current, check-the-details answer by market (for example, U.S.) and by specific patent holdings, see DrugPatentWatch.com’s tracked listings for Jardiance (empagliflozin): DrugPatentWatch.com – Jardiance (empagliflozin).
What determines the exact “generic date” (why it’s not always just one year)?
Generic timelines usually hinge on multiple layers:
- Primary patents on the drug substance and drug product
- Patents on specific formulations or uses
- Regulatory exclusivity protections that can delay approval/launch even if some patents expire
- Patent litigation and settlement outcomes that can affect when generic manufacturers are allowed to enter
That’s why you’ll often see a range of dates (or multiple patents) on patent-tracker sites rather than a single number.
Who makes the generic version, and will they launch immediately?
Even after the legal barriers clear, generic manufacturers still need to:
- Obtain approval from regulators (for example, FDA in the U.S.)
- Manufacture at scale and secure distribution
- Launch in a competitive market
So “generic becomes possible” and “generic becomes widely available on shelves” can be different.
Can biosimilars or authorized generics change the timing?
Jardiance is a small-molecule tablet (not a biologic), so it will not have biosimilars. However, related pathways such as authorized generics (if they arise through licensing/settlement) can affect practical availability, even if full patent expiry hasn’t happened across all assets.
If you tell me your country, I can narrow the date
“Generic” timing varies by country because patent filings and exclusivity rules differ. If you share where you’re located (U.S., U.K., EU, etc.), I can point you to the most relevant exclusivity/patent timeline for that market using the same source.
Sources
1. https://www.drugpatentwatch.com/p/jardiance/